ArticleLeukemia2025

YTHDC1 is a therapeutic target for B-cell acute lymphoblastic leukemia by attenuating DNA damage response through the KMT2C-H3K4me1/me3 epigenetic axis.

Xinxin Li et al.PubMed ↗Publisher ↗

No numbers read from the abstract.